LOGO

You are here: 

  • Home

 


News from members

  • NorDiag's kick start for an exciting 2010

    NorDiag's strong growth for the Company's core business continued in 2009, giving a total operating revenue growth of 43 % for 2009 compared to 2008. The restructuring of the Company is completed and the operation is financially secured towards a break-even quarter in 2011. "2010 will be an exciting year for NorDiag," comments CEO Mårten Wigstøl.

    >> Read more19.02.10

  • A transformational year for Algeta ASA

    "2009 was a transformational year for Algeta during which we successfully delivered a number of major milestones in progressing  towards our objective of creating a focused oncology company," said Andrew Kay, Algeta's President and CEO. The results for the last quarter and full year 2009 were presented in Oslo Friday.

    >> Read more19.02.10

  • NorDiag: Cooperation agreement with Molzym

    NorDiag and Molzym have combined their techno-logies into an integrated system for automated molecular detection of pathogens, among others for sepsis testing. The companies have signed a collaboration agreement regarding sale of an integrated solution for sepsis testing and more.

    >> Read more17.02.10

  • "A major milestone for NorDiag ASA"

    NorDiag ASA and Hain Lifescience GmbH have entered into an OEM agreement for the Arrow instrument and for sample preparation reagents to be used in connection with Hain Lifescience molecular biological assays. "This is a major milestone for the Company," says CEO of NorDiag Mårten Wigstøl (pictured).

    >> Read more15.02.10

  • Ny medarbeider i Norsk Biotekforum

     Maria Olsson (bildet) er sivilingeniør i molekylær bioteknikk fra Uppsala Universitet og har en tileggsutdannelse fra Chalmers entreprenørskole. Hun tar nå fatt på jobben som prosjektleder for Norsk Biotekforums Life Science Support Office.

    >> Read more10.02.10

  • DiaGenic and Ferrer inCode Sign Distribution Agreement

    DiaGenic ASA and Ferrer inCode have signed a distribution agreement for the blood-based ADtect test for early diagnosis of Alzheimer’s disease covering a total of 32 countries. The agreement gives Ferrer inCode the exclusive right to sell and market ADtect initially in Germany, Belgium, the Netherlands, Luxemburg, France, Italy, Spain and Portugal followed by Latin America.

    >> Read more21.01.10

  • Strong anti-tumour response observed by PCI Biotech

    PCI Biotech has completed the treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients. "We are very excited by the positive results", says PCI Biotech CEO Per Walday.

     

    >> Read more21.01.10

  • Nutri Pharma ASA launches offer for Bionor Immuno AS

    Nutri Pharma ASA has submitted a voluntary exchange offer for all outstanding shares in Bionor Immuno AS. The shareholders of Bionor will be offered 1 Nutri Pharma share per 2 shares in Bionor Immuno AS. -- We are very excited about the prospects, says Trond Syvertsen (picture), CEO of Nutri Pharma ASA.

    >> Read more19.01.10

  • Algeta and IFE agree to collaborate

    Algeta ASA, the cancer therapeutics company, and the Institute for Energy Technology (IFE), the international research institute for energy and nuclear technology based in Oslo, have agreed to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials.

    >> Read more18.01.10

  • NorDiags share offering heavily oversubscribed

    NorDiag has received subscriptions for approximately 19,2 million shares in the subsequent offering closed today. This represents approximately 240 percent of the total number of offered shares.  - We are most satisfied with this oversubscription, which we interpret as shareholders confidence in our recent performance and strategy going forward, says CEO Mårten Wigstøl (picture).

    >> Read more13.01.10

Showing from 1 to 10 of total 71 articles

Events

    >> All events

 

 


 

Norwegian Bioindustry Association

Middelthuns gt. 27, Postboks 7072 Majorstuen, NO-0306 Oslo Tel: +47 23 08 88 00 / +47 23 08 88 18 / +47 91 10 54 91 Email: biotek@norskindustri.no Fax: +47 23 08 88 98